Abstract
PurposeTo investigate the potential of two flow imaging microscopy (FIM) techniques (Micro-Flow Imaging (MFI) and FlowCAM) to determine total cell concentration and cell viability.MethodsB-lineage acute lymphoblastic leukemia (B-ALL) cells of 2 different donors were exposed to ambient conditions. Samples were taken at different days and measured with MFI, FlowCAM, hemocytometry and automated cell counting. Dead and live cells from a fresh B-ALL cell suspension were fractionated by flow cytometry in order to derive software filters based on morphological parameters of separate cell populations with MFI and FlowCAM. The filter sets were used to assess cell viability in the measured samples.ResultsAll techniques gave fairly similar cell concentration values over the whole incubation period. MFI showed to be superior with respect to precision, whereas FlowCAM provided particle images with a higher resolution. Moreover, both FIM methods were able to provide similar results for cell viability as the conventional methods (hemocytometry and automated cell counting).ConclusionFIM-based methods may be advantageous over conventional cell methods for determining total cell concentration and cell viability, as FIM measures much larger sample volumes, does not require labeling, is less laborious and provides images of individual cells.
Highlights
Electronic supplementary material The online version of this article contains supplementary material, which is available to authorized users.Guest Editors: Karin Hoogendoorn and Christopher A
The total cell concentration and morphological parameters of each sample were analyzed at different days by using Micro-Flow Imaging (MFI) and FlowCAM
The results indicate that all the techniques gave fairly similar total cell concentrations
Summary
Guest Editors: Karin Hoogendoorn and Christopher A. Cell-based medicinal products (CBMPs) are receiving increasing attention by the pharmaceutical industry because of their potential in treatment of a variety of diseases, such as cancers, viral infections, and autoimmune disorders [1,2]. Like for any other pharmaceutical drug product, the quality of CBMPs highly determines their safety and efficacy [3]. The safety of a CBMP depends, amongst others, on the presence of cellular and non-cellular impurities. When a specific cell type is required for the therapy, unwanted cell populations are considered impurities and should be tested and
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
